Kailera Therapeutics and Hengrui Pharma are stepping into the obesity ring with strong Phase II data for their dual agonist of GLP-1 and GIP for overweight and obesity HRS9531, also known as KAI-9531, which Hengrui is moving through Phase III development in China and which they plan to develop in a global Phase III program as well. The companies see the potential for potentially greater weight loss given the lack of a plateau at 36 weeks.
Kailera/Hengrui’s GLP-1/GIP Agonist Candidate Could Have Better Efficacy
The companies announced Phase II data showing a 22.8% mean weight reduction, but with no plateau, suggesting potentially further weight loss as time goes on.
More from Alimentary/Metabolic
More from Scrip
• By
In this week's episode: Merck & Co. licenses Hengrui’s lipid lowerer; Novo gets United’s triple G obesity drug; J&J plans major US manufacturing investments; approval for GSK’s novel antibiotic; and a call for more aggressive Korean M&A activity.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.